Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kilitch Drugs (India)NSE:KILITCH -0.13%85 EV-to-EBIT is 13.27 as of Aug. 24, 2026, which is 42% below its 10-year median of 22.85. GuruFocus rates NSE:KILITCH with a GF Score™ of 85/100 and a GF Value™ of ₹229.23 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 694 Drug Manufacturers companies, Kilitch Drugs (India) ranks better than 56.48% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kilitch Drugs (India)'s Enterprise Value for the quarter that ended in Jun. 2026 was ₹6,834 Mil.
Kilitch Drugs (India)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹440 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kilitch Drugs (India) EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kilitch Drugs (India)'s EV-to-EBIT falls into.
Kilitch Drugs (India)'s current Enterprise Value is ₹5,836 Mil.
Kilitch Drugs (India)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹440 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kilitch Drugs (India) (NSE:KILITCH) has a EV-to-EBIT of 13.27 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kilitch Drugs (India) and its competitors. This is 42% below median its historical median of 22.85. Over the past decade, Kilitch Drugs (India)'s EV-to-EBIT has ranged from 10.33 to 2,850.87. According to the industry distribution chart, Kilitch Drugs (India) ranks #302 out of 694 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is Kilitch Drugs (India)'s EV-to-EBIT too high?
Kilitch Drugs (India)'s current EV-to-EBIT of 13.27 is 42% below median its 10-year median of 22.85. Over the past 10 years, this metric has ranged from a low of 10.33 to a high of 2,850.87. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Kilitch Drugs (India)'s value of 13.27 is 15.3% below this industry median. Based on the distribution chart, Kilitch Drugs (India) ranks #302 out of 694 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kilitch Drugs (India) has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kilitch Drugs (India) ranks #302 out of 694 companies for EV-to-EBIT. This puts Kilitch Drugs (India) in the upper half of its industry. The industry median EV-to-EBIT is 15.66. Kilitch Drugs (India)'s value of 13.27 is 15.3% below this benchmark. Historically, Kilitch Drugs (India)'s own EV-to-EBIT has ranged from 10.33 to 2,850.87 over the past decade. While the company's 10-year median is 22.85 vs. the industry median of 15.66, Kilitch Drugs (India) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kilitch Drugs (India)'s current EV-to-EBIT of 13.27 is 15.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kilitch Drugs (India) and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kilitch Drugs (India)'s current EV-to-EBIT is 13.27, which is 42% below median its own 10-year median of 22.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹229.23, compared to a current price of ₹162.33 — trading 29.2% below its estimated fair value. The current EV-to-EBIT is 13.27, which is 42% below median its 10-year median of 22.85 and 15.3% below the Drug Manufacturers industry median of 15.66. Kilitch Drugs (India)'s overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current EV-to-EBIT is 13.27 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?
Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued.
The current stock price of ₹162.33 is trading 29.2% below its estimated GF Value™ of ₹229.23.
GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.
Key valuation signals for NSE:KILITCH:
EV-to-EBIT: 13.27 (42% below median its 10-year median of 22.85)
GF Value™: ₹229.23 vs. price of ₹162.33 (29.2% below fair value)
Industry Position: 15.3% below the Drug Manufacturers median (#302 of 694)
No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
85GF Score
Get the complete analysis for NSE:KILITCH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KILITCH has been successfully added to your 
